BPC 157 peptide therapy for injury recovery and gut health Beyond a singular focus on GLP 1: why we need a new nomenclature now The Lancet Diabetes & Endocrinology CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide ( GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current BPC 157 Side Effects: Myths, Realities, and How to Use It Safely Optimum Peak Wellness Too often, BPC 157 gets boxed into a single use: injury recovery. Gabriel Alizaidy, MD, MS Heal and Maximize Your Performance with BPC 157 Dr. Neil Paulvin